Clinical Trial: National Registry of IgG4-RD in China

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational [Patient Registry]

Official Title: National Registry of IgG4-RD in China

Brief Summary:

The aim of this study is to establish a nation-wide cohort study of IgG4-related disease (IgG4-RD) in China.

Methods: All the patients fulfilling diagnostic criteria of IgG4-RD (2011) would be enrolled from multi-centers around China. A online database system has been established.

Endpoints: The primary endpoint is to investigate the clinical manifestations of Chinese IgG4-RD patients; the secondary endpoints including the demographic features,laboratory characteristics, immunological tests, imaging and pathological features, in addition, the treatment and prognosis of the disease.


Detailed Summary:

This is a multicenter registry study of IgG4-RD patients. Newly diagnosed IgG4-RD patients will be recruited from allover the China. Inclusion criteria: patients with definite, probable, or possible IgG4-RD according to the 2011 comprehensive diagnostic criteria for IgG4-RD will be recruited. Exclusion criteria: patients with malignancy or other autoimmune diseases are excluded.

The data will be uploaded through the platform of Chinese Rheumatology Information Platform. Demographic data, initial symptoms, disease duration, history of allergy, and physical examination, organ involvements, laboratory findings, radiological and pathological results, as well as treatment, side effects will be recorded.

This study was approved by the Medical Ethics Committee of PUMCH (Beijing, China). All patients will signe informed consent.

Statistical Analysis: All parameters are described in the standard summary statistics, including mean, standard deviation, minimum, and maximum. All statistical analyses will be performed by SPSS.

Endpoints: The primary endpoint is to investigate the organ involvements of Chinese IgG4-RD patients. The secondary endpoints including the demographic features,laboratory characteristics, immunological tests, imaging and pathological features, in addition, the treatment and prognosis of the disease.


Sponsor: Peking Union Medical College Hospital

Current Primary Outcome: Organ involvements of Chinese IgG4-RD patients [ Time Frame: 5 years ]

To calculate the percentage of organ involvements in at least 900 patients.


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Response rate of glucocorticoids and immunosuppressants on IgG4-RD in China [ Time Frame: 5 years ]
  • Relapse rate of IgG4-RD patients in China [ Time Frame: 5 years ]
  • The correlation between baseline disease activities and relapse rate. [ Time Frame: 5 years ]
  • The incidence rate of tumor in IgG4 related disease patients in China. [ Time Frame: 5 years ]
  • Ten year survival rate of patients with IgG4 related disease in China. [ Time Frame: 10 years ]
  • The imaging features of involved organs. [ Time Frame: 3 years ]
  • The sensitivity and specificity of IgG4 positive plasma cells in pathological diagnosis of IgG4 related disease. [ Time Frame: 3 years ]


Original Secondary Outcome:

  • Response rate of glucocorticoids and immunosuppressants on IgG4-RD in China [ Time Frame: 5 years ]
  • Relapse rate of IgG4-RD patients in China [ Time Frame: 5 years ]
  • The correlation between baseline disease activites and relapse rate. [ Time Frame: 5 years ]
  • The incidence rate of tumor in IgG4 related disease patients in China. [ Time Frame: 5 years ]
  • Ten year survival rate of patients with IgG4 related disease in China. [ Time Frame: 10 years ]
  • The imaging features of involved organs. [ Time Frame: 3 years ]
  • The sensitivity and specificity of IgG4 positive plasma cells in pathological diagnosis of IgG4 related disease. [ Time Frame: 3 years ]


Information By: Peking Union Medical College Hospital

Dates:
Date Received: January 2, 2017
Date Started: December 2016
Date Completion: December 2026
Last Updated: January 23, 2017
Last Verified: January 2017